StonvexLoading…
StonvexStonvexStonvexCore line items from BIOX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-06-30 | Annual 2024 2024-06-30 | Annual 2023 2023-06-30 | Annual 2022 2022-06-30 |
|---|---|---|---|---|
Revenue | $335.11M | $464.78M | $420.06M | $334.84M |
Operating Income | $-2.24M | $45.85M | $54.18M | $39.87M |
Net Income | $-58.85M | $7.29M | $20.17M | $-3.91M |
EPS (Diluted) | $-0.88 | $0.07 | $0.30 | $-0.17 |
Total Assets | $763.65M | $852.55M | $818.06M | $518.22M |
Total Liabilities | $468.43M | $501.17M | $487.56M | $359.92M |
Cash & Equivalents | $32.70M | $44.47M | $48.13M | $33.48M |
Free Cash Flow OCF − CapEx | $44.26M | $31.93M | $-8.77M | $-20.97M |
Shares Outstanding | Not available | Not available | Not available | Not available |